Highest-materiality recent filing
Cocrystal Pharma stockholders elect directors and ratify auditor at 2026 annual meeting
Elected five directors: Kornberg, Frost, Hassan, Pfenniger, Rubin; each received >5.9M votes for.
Cocrystal Pharma appoints James Sapirstein as CEO, replacing co-CEOs Lee and Martin
James Sapirstein appointed CEO effective June 3, 2026; prior CEO of Entero Therapeutics (Nasdaq: ENTO).
Cocrystal Pharma appoints James Sapirstein as CEO, replacing co-CEOs Sam Lee and Jim Martin
James Sapirstein appointed CEO effective June 3, 2026, replacing Sam Lee and Jim Martin as co-CEOs.
Cocrystal Pharma announces discovery of pan-viral inhibitors with <50 nM potency against hantavirus
Novel pan-viral inhibitors target L-protein of Andes hantavirus; IC50 <50 nM against hantaan virus in vitro.
CDI-988 mechanism and Phase 1b human challenge study featured at ICAR 2026 in Prague.
Cocrystal Pharma receives FDA Fast Track designation for norovirus antiviral CDI-988
FDA granted Fast Track designation for oral, direct-acting protease inhibitor CDI-988 for norovirus.
Net loss $8.8M ($0.78/sh) vs $17.5M ($1.72/sh) in 2024; R&D spend down to $5.1M from $12.5M.
Cocrystal Pharma board member Dr. Anthony Japour passes away on March 10, 2026
Dr. Anthony Japour, a member of Cocrystal Pharma's board of directors, died on March 10, 2026.
Cocrystal Pharma doses first subjects in Phase 1b norovirus challenge study for CDI-988
First subjects dosed in Phase 1b challenge study (NCT07198139) at Emory University evaluating CDI-988 for norovirus prevention and treatment.
Cocrystal Pharma's CDI-988 oral norovirus inhibitor to be featured at ICAR 2026
CDI-988 is the first oral antiviral drug candidate developed for prevention and treatment of norovirus infections.
Cocrystal Pharma grants stock options to directors, officers, and consultant under 2025 Plan
Non-qualified stock options granted to 7 directors, 2 executive officers, and 1 consultant, vesting over 1-2 years.
IRB approval from Emory University to initiate Phase 1b human challenge study with CDI-988 for norovirus prevention and treatment.
Cocrystal Pharma to present at NobleCon 21 on Dec 3, 2025
CFO/co-CEO James Martin to give Company overview and clinical progress update.
Cocrystal Pharma Reports Q3 2025 Net Loss of $2.0M, Provides Norovirus and Influenza Program Updates
Received FDA IND clearance for CDI-988 as norovirus preventive and treatment; Phase 1b challenge study expected to begin Q1 2026.
Cocrystal Pharma raises $1.03M in private placement with four insider investors at $1.39/unit
Sold 739,426 units (1 share + 2 warrants) at $1.39/unit for $1.03M to four accredited insider purchasers.
Cocrystal Pharma receives ~$500K NIH SBIR award for influenza antiviral program
Award from NIH/NIAID to support development of novel oral broad-spectrum antiviral for influenza A and B.
Cocrystal Pharma closes $4.7M registered direct offering with warrant coverage
Gross proceeds of ~$4.75M from sale of 2,764,710 shares at $1.70 each.
Cocrystal Pharma announces up to $13M registered direct offering at $1.70/share
$4.7M upfront from sale of 2,764,710 shares at $1.70; closing expected Sep 15, 2025.
President/co-CEO Sam Lee presented CDI-988 Phase 1 data at 9th International Calicivirus Conference (Sept 7–11) in Banff.
Cocrystal Pharma Q2 2025 net loss narrows to $2.1M; cash at $4.8M; CDI-988 Phase 1 data positive
Q2 2025 net loss of $2.1M ($0.20/share) vs $5.3M ($0.53/share) in Q2 2024, primarily on lower R&D costs.
Cocrystal Pharma: Phase 1 CDI-988 well tolerated; Phase 1b planned for norovirus
All CDI-988 doses (100-1200 mg) well tolerated in Phase 1 SAD and MAD cohorts; no severe AEs.
Cocrystal to present Phase 1 data for norovirus inhibitor CDI-988 at Calicivirus Conference
CDI-988 is a first-in-class pan-viral protease inhibitor targeting norovirus and coronaviruses.
Cocrystal Pharma shareholders elect directors, ratify auditor, approve 2025 equity plan
Elected six directors: Kornberg (4,386,691 for), Frost (4,344,444 for), Hassan (4,440,602 for), Japour, Pfenniger, Rubin.
Cocrystal Pharma reduces stockholder meeting quorum to one-third
Board approved bylaw amendment on June 17, 2025 reducing quorum to one-third of voting power.
Cocrystal Pharma's norovirus antiviral CDI-988 to be presented at MHSRS in August 2025
CDI-988, a broad-spectrum protease inhibitor, will be featured in an oral presentation at the 2025 Military Health System Research Symposium on August 4, 2025 in Kissimmee, Florida.
CC-42344 exhibited EC50 of 0.003 µM against the 2024 Texas H5N1 strain, ~1,000-fold more potent than Tamiflu (EC50 2.69 µM).
Net loss for Q1 2025 was $2.3M ($0.23/share) vs $4.0M ($0.39/share) in Q1 2024.
CDI-988 demonstrated potent binding to conserved region of GII.17 protease, comparable to activity against GII.4 variants.
Cocrystal Pharma furnishes corporate presentation with no material new disclosures
Filed an investor presentation on April 23, 2025 under Item 7.01 Regulation FD.
Cocrystal Pharma adopts 2025 Equity Incentive Plan with 1.5M initial shares
Plan effective March 31, 2025; shareholder approval required under Nasdaq rules.
Cocrystal Pharma files corrected auditor consent referencing S-3 registration
Corrected Weinberg & Company consent for Form S-3 (No. 333-271883) filed as Exhibit 23.1.
Cocrystal Pharma FY2024 net loss $17.5M; cash $9.9M; pipeline advances
Net loss of $17.5M ($1.72 per share) for FY2024, vs. $18.0M ($1.87) in 2023; R&D expenses $12.5M.
Filing under Item 7.01 for an investor presentation dated January 13, 2025.
Phase 1 MAD study shows CDI-988 well-tolerated up to 800 mg/day for 10 days; new cohort at 1,200 mg for 5 days planned.
Cocrystal Pharma extends Phase 2a flu study due to low infection rate, data uninterpretable
No SAEs or drug-related discontinuations in Phase 2a study of oral PB2 inhibitor CC-42344.
Cocrystal Pharma Q3 net loss $4.9M; cash $13M; expects topline data from two studies soon
Net loss Q3 2024 of $4.9M ($0.49 per share) vs $4.2M ($0.41) in Q3 2023 which included $1.6M legal settlement.
CC-42344 showed in vitro activity against avian influenza A (H5N1) PB2 protein; high-resolution crystal structure confirmed binding.
Cocrystal Pharma ratifies exec salary hikes to $416K, $200K bonuses, and RSU grants
James Martin (CFO/co-CEO) and Dr. Sam Lee (President/co-CEO) base salary increased from $400K to $416K, plus $200K bonus and 40,000 RSUs each.
Cocrystal Pharma to present at two investor conferences; outlines near-term clinical milestones
Expects to report topline results from influenza A Phase 2a challenge study (CC-42344) in 2024, final report in 2025.
Cocrystal Pharma posts Q2 net loss $5.3M, cash $18.1M; pipeline milestones set
Q2 2024 net loss $5.3M ($0.54/sh) vs Q2 2023 net loss $4.2M ($0.41/sh); R&D spend $4.3M up 54% YoY.
Cocrystal Pharma reports favorable Phase 1 SAD results for CDI-988 oral pan-viral protease inhibitor
CDI-988 showed favorable safety and tolerability in SAD cohorts; doses from 100 mg to 600 mg.
Shareholders approved reducing authorized capital to 100M common + 1M preferred shares; amendment effective June 27, 2024.
Cocrystal Pharma reports CC-42344 active against avian H5N1 PB2; Phase 2a results expected H2 2024
In vitro studies show CC-42344 inhibits the PB2 protein of avian influenza A (H5N1) strain from infected dairy cattle.
Cocrystal Pharma Q1 net loss $4.0M ($0.39/shr); cash $21.8M; pipeline milestones on track
Net loss improved to $4.0M ($0.39/shr) from $5.2M ($0.64/shr) in Q1 2023.
Cocrystal Pharma completes enrollment of 78 subjects in Phase 2a study of CC-42344 for influenza A
Enrolled 78 healthy subjects in randomized, double-blind, placebo-controlled Phase 2a human challenge study of oral PB2 inhibitor CC-42344.
Net loss $18.0M ($1.87/share) vs $38.8M ($4.77/share) prior year which included $19.1M goodwill impairment.
Cocrystal Pharma gets FDA Pre-IND feedback on oral CC-42344 for influenza A
Received FDA Pre-IND written response to January 2024 submission for oral CC-42344.
Cocrystal terminates license agreements with Kansas State due to futility; retains CDI-988
On Feb 28, 2024, Cocrystal notified Kansas State University Research Foundation of termination of two License Agreements (Feb 12, 2020 and Apr 19, 2020), effective March 29, 2024.
Cocrystal Pharma provides corporate presentation; details not disclosed in filing
Cocrystal Pharma (COCP) presented to the investment community on January 8, 2024.
CDI-988 (pan-norovirus/coronavirus 3CL protease inhibitor) Phase 1 in Australia shows favorable safety in single-ascending dose cohorts.
Mr. Sapirstein replaces Sam Lee and James Martin, who served as the Company’s Co-Chief Executive Officers.
Mr. Sapirstein replaces Sam Lee and James Martin, who served as the Company’s Co-Chief Executive Officers.
the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed James Sapirstein as the Chief Executive Officer of the Company, effective immediately
On April 20, 2023, the Board of Directors of Cocrystal Pharma, Inc. (the “Company”) appointed Fred Hassan as a director, thereby increasing the number of directors to six.
Max materiality 0.75 · Median 0.55 · Most common event other_material